about
sameAs
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical StatusPretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistryApplication of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinomaNatural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) miceDiannexin protects against renal ischemia reperfusion injury and targets phosphatidylserines in ischemic tissueDrosomycin-like defensin, a human homologue of Drosophila melanogaster drosomycin with antifungal activity.Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND).Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines.Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes.Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy.Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.Surface modifications by gas plasma control osteogenic differentiation of MC3T3-E1 cells.Imaging integrin alpha-v-beta-3 expression in tumors with an 18F-labeled dimeric RGD peptide.Preclinical evaluation of PAC1 targeting with radiolabeled Maxadilan.Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts.Response Monitoring with [18F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases.Perfluorocarbon/Gold Loading for Noninvasive in Vivo Assessment of Bone Fillers Using 19F Magnetic Resonance Imaging and Computed Tomography.68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.A novel facile method of labeling octreotide with (18)F-fluorineMolecular imaging of angiogenesis with SPECT.Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.PET imaging of αvβ₃ integrin expression in tumours with ⁶⁸Ga-labelled mono-, di- and tetrameric RGD peptides.Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas.Fluorinated amino acids for tumour imaging with positron emission tomography.Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient miceApplication of metal-free triazole formation in the synthesis of cyclic RGD-DTPA conjugates.Nuclear medicine imaging to predict response to radiotherapy: a review.Preclinical evaluation of 68Ga-DOTA-minigastrin for the detection of cholecystokinin-2/gastrin receptor-positive tumors.Comparative biodistribution of 12 ¹¹¹In-labelled gastrin/CCK2 receptor-targeting peptidesPretargeted radioimmunotherapy of cancer: progress step by step.Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients.Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC.Monoclonal antibody-based therapy for renal cell carcinoma.Monoclonal antibody therapy of kidney cancer.Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amountOptimized labeling of NOTA-conjugated octreotide with F-18.Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method.
P50
Q26774920-E8B12F14-144F-4E37-8016-BE052871911DQ27026010-13F2165E-6CDD-4F8C-B439-D14632682C7CQ27026961-83C06CD3-49EA-45EC-8632-DFEA519CB9C2Q27318729-AEC8B6CC-C74F-463D-A9C5-B836544D8413Q28740637-5C41A957-1BFB-489F-B9C9-EAAC4B73BE01Q29871460-57525B77-B168-4709-A7E1-77D8A0C8FF3DQ31077062-74990222-CE6F-47BB-A9B9-9578E1F112B2Q33219689-915A31C0-7BE9-43B6-810F-11EB8240A138Q33373408-E7A99AFF-8EA1-42A2-9072-4BB57576E52BQ33414032-7C5ACC21-F8F4-4A79-BC6E-C653483CE817Q33427043-2A134A21-5195-470F-B144-72FBB481056AQ33428697-28531AA6-79F5-4EAC-836D-4273EDE20E07Q33454230-15AB940E-902C-4439-8706-BD406C71446EQ33668360-D5C651E5-FEE3-4FF5-90AD-A93640893741Q33687453-5013FD9C-4216-4FCE-96C2-B4A490E99E5EQ33780787-2626DA99-BA55-4A07-B6CA-5F9F3907A8EEQ33875886-B6433048-347E-4AFF-ADB5-192BB0F10BA5Q33903721-C2D070FB-5F53-44CA-9F0B-79B98C8E4CE3Q33915233-7930FC11-F5DB-4C58-9ABD-BD5764C9E9CEQ34012587-AFBEC8AC-7951-492A-A866-7CB3ECA9A610Q34040149-59832D0E-78CF-4789-88A1-8EC87ACACCFAQ34210499-BE4FD6D7-3B69-4399-8503-0F2E046CD070Q34420335-36833092-416A-4511-B27D-032EC6A52D07Q34579936-4EE2C81D-0A91-447A-B825-850585A7E805Q34614811-07084AE3-1DDD-421B-A54F-603BFD187A21Q34647984-66B4CBEC-5904-416C-B76A-9DE0FAF41959Q34795546-C1C4206A-E420-4E63-B5BA-2C4414B73C23Q35035111-79432179-39E3-440C-BEE2-55B771744FCEQ35069148-6CBE3A3F-7F13-4903-B47F-F328B73B5E57Q35078943-77CCB254-6D5B-42CC-9F03-71FE0D1E3048Q35079412-416B43A4-E7D3-48AB-A3B4-089137E490F8Q35100621-40B0E84D-142B-40A4-8400-9DE8A34DF79DQ35152565-4DA9F1A1-9907-4CBA-9645-79A7C0A43637Q35211004-3E2C88C2-A4AF-48DF-9E17-D88895FE8CD4Q35598280-DF853666-AD63-4E97-826C-0F0FDD8926A3Q35627019-E4E13F76-C1CB-49AF-BDBD-5EEABF850D08Q35632475-3BC25A4D-B9B9-4CD3-BDE1-79719D929D51Q35675498-9ED777A8-0B68-4511-AEBC-915A98D9DF32Q35810016-B9E4432B-AD73-4B38-902A-0CCB4980DE9FQ35819169-E6991478-DEE3-4D6F-9238-E023F92BE092
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Otto C Boerman
@ast
Otto C Boerman
@es
Otto C Boerman
@nl
Otto C. Boerman
@en
type
label
Otto C Boerman
@ast
Otto C Boerman
@es
Otto C Boerman
@nl
Otto C. Boerman
@en
altLabel
Boerman O
@en
Boerman O. C.
@en
Boerman O.
@en
Boerman OC
@en
Boerman
@en
O Boerman
@en
O C Boerman
@en
O. Boerman
@en
O. C. Boerman
@en
Otto Boerman
@en
prefLabel
Otto C Boerman
@ast
Otto C Boerman
@es
Otto C Boerman
@nl
Otto C. Boerman
@en
P21
P31
P496
0000-0001-6832-101X